LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

作者： James Chih-Hsin Yang , Martin H. Schuler , Nobuyuki Yamamoto , Kenneth John O'Byrne , Vera Hirsh

DOI: 10.1200/JCO.2012.30.15_SUPPL.LBA7500

关键词:

摘要: LBA7500 The full, final text of this will be available at .asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this will be printed in the Monday edition of ASCO Daily News.

ascopubs.org 本地加速

doi.org 本地加速

sci-hub.st HTML 下载加速

参考文章(0)

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

来源期刊

我的账户

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

来源期刊

相似文章 10

我的账户